[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-364961-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-364961-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","biopsy-derived-organoids-in-personalised-early-breast-cancer-care-challenges-of-tumour-purity-and-normal-cell-overgrowth-cap-their-practical-utility","Biopsy-derived organoids in personalised early breast cancer care - Challenges of tumour purity and normal cell overgrowth cap their practical utility","","Establishing organoids containing exclusively tumour cells, rather than healthy counterparts, is a prerequisite for clinical translation. Organoids are widely used to expand patient material and create modifiable 3D models for translational research and personalised medicine, including functional drug testing. Using untreated early-stage primary breast cancer biopsies, tumour organoid culture shows major limitations, with frequent overgrowth of genetically normal, noncancerous epithelial cells.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/biopsy-derived-organoids-in-personalised-early-breast-cancer-care-challenges-of-tumour-purity-and-normal-cell-overgrowth-cap-their-practical-utility/364961/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/biopsy-derived-organoids-in-personalised-early-breast-cancer-care-challenges-of-tumour-purity-and-normal-cell-overgrowth-cap-their-practical-utility/364961.png","ImageObject",300,407,{"name":42,"@type":43},"Genevieve","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-14","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",14,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is tumour-only organoid generation important for clinical use?","Question",{"text":63,"@type":64},"Tumour-only organoids are essential because clinical translation requires models that reflect patient cancer cells rather than healthy overgrowth, enabling reliable assessment and downstream applications.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What major challenge did the study observe when culturing early breast cancer organoids?",{"text":68,"@type":64},"The study found frequent outgrowth of genetically normal, noncancerous epithelial cells, indicating that consistent tumour organoid establishment from early biopsy material is difficult.",{"name":70,"@type":61,"acceptedAnswer":71},"How do the authors assess the success of tumour cell culture?",{"text":72,"@type":64},"The authors present time- and cost-efficient methods for assessing successful tumour cell culture, reporting a high rate of normal cell overgrowth in early-stage breast cancer organoids.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},364961,1790519338,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":124,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1374391974585,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","DOI: 10.1002/ijc.35386  \nRES EARCH A RTICLE  \nInnovative Tools a n d M ethods  \nBiopsy-derived organoids in personalised early breast cancer care: Challenges of tumour purity and normal cell overgrowth cap their practical utility  \nPaul Schwerd-Kleine 1,2,3 | Roberto Würth 1,2 | Tasneem Cheytan 1,2,3 |  \nLaura Michel 4 | Verena Thewes 5 | Ewgenija Gutjahr 1,2,6 | Huriye Seker-Cin 6 | Daniel Kazdal 6  | Sarah-Jane Neuberth 1,2,3 | Vera Thiel 1,2,3 |  \nJonas Schwickert 1,2,3 | Tim Vorberg 1,2,3 | Jennifer Wischhusen 1,2 | Albrecht Stenzinger 6  | Marc Zapatka 5 | Peter Lichter 5,7 | Andreas Schneeweiss 4 | Andreas Trumpp 1,2 | Martin R. Sprick 1,2   \n1Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany  \n2Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEMgGmbH), Heidelberg, Germany  \n3Faculty of Biosciences, Heidelberg University, Heidelberg, Germany  \n4Division of Gynecologic Oncology, National Center for Tumor Diseases (NCT), Heidelberg, Germany  \n5Division of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany 6Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany  \n7National Center for Tumor Diseases (NCT), Heidelberg, Germany  \nCorrespondence  \nMartin R. Sprick and Andreas Trumpp, Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ), Heidelberg 69120, Germany. Email: martin.sprick@hi-stem.de and a.trumpp@ dkfz-heidelberg.de  \nFunding information  \nDeutsche Krebshilfe, Grant/Award Number: 70113450; Bundesministerium für Bildung und Forschung, Grant/Award Numbers:  \n01KD2206B, 01KD2206E; Dietmar Hopp Foundation; NCT Heidelberg; Dieter Morszeck Foundation  \nAbstract  \nThe ability to establish organoids composed exclusively of tumour rather than healthy cells is essential for their implementation into clinical practice. Organoidshave recently emerged as a powerful tool to expand patient material in culture and generate modifiable 3D models derived from humans or animal models. For translational research, they enable the creation of model systems for an ever-increasing number of cell types and diseases. And in personalised medicine, they potentially allow for functional drug testing with high predictive power in certain settings. We found that using biopsy material from untreated, early-stage primary breast cancer patients poses significant challenges for consistently culturing tumour cells as organoids. Specifically, we observed frequent outgrowth of genetically normal, noncancerous epithelial cells. We analysed >100 biopsy samples from early-stage breast cancer and present our large collection of >70 organoid lines. We also show methods of assessing successful tumour cell culture in a time, and cost-efficient manner, proving a high rate (>85%) of normal cell overgrowth in early-stage breast cancer organoids. Finally, we show a number of successful attempts to culture cancer organoids from mastectomy-derived tissue of advanced, metastatic breast cancer. We conclude that the usefulness of organoids from early breast cancer for translational research and personalised medicine, especially guidance of adjuvant or post-surgical maintenance therapy, is strongly limited by the low success rate of culturing cancerous cells under organoid conditions.  \nAndreas Trumpp and Martin R. Sprick contributed equally to this work.  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \n© 2025 The Author(s) . International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.  \nKEYWOR DS  \nbreast cancer, genomics, organoids, personalized medicine, quality control  \nWhat's New?  \nBreast cancer patients often face relapse, sometimes years after initially successful therapy. It would therefore be highly desirable to develop a platform enabling routin","cbCaidJSx5ERmif4","https://ap.wps.com/l/cbCaidJSx5ERmif4","pdf",5776058,"English","# Abstract\n## Introduction\n## What's New","[{\"question\":\"Why is tumour-only organoid generation important for clinical use?\",\"answer\":\"Tumour-only organoids are essential because clinical translation requires models that reflect patient cancer cells rather than healthy overgrowth, enabling reliable assessment and downstream applications.\"},{\"question\":\"What major challenge did the study observe when culturing early breast cancer organoids?\",\"answer\":\"The study found frequent outgrowth of genetically normal, noncancerous epithelial cells, indicating that consistent tumour organoid establishment from early biopsy material is difficult.\"},{\"question\":\"How do the authors assess the success of tumour cell culture?\",\"answer\":\"The authors present time- and cost-efficient methods for assessing successful tumour cell culture, reporting a high rate of normal cell overgrowth in early-stage breast cancer organoids.\"}]","Biopsy-derived organoids in personalised early breast cancer care - Challenges of tumour purity and normal cell overgrowth cap their practical utility | PDF",1790159537,25,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d12163dc4850babbd5de6ac35b823ba7.webp",983,1291,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/72b50fa188bd4c9f545e8a3ecbc01769.webp",982,1290,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/63eed8dfb36414ab66597a7e688bcb36.webp",981,1289,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ab6d637fbf550cbd4190b82d6fcce844.webp",980,1287]